Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac Disease
Public ClinicalTrials.gov record NCT00620451. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIb, Randomized, Double-Blind, Placebo Controlled Study for the Treatment of Active Celiac Disease With Larazotide Acetate (AT-1001)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study was conducted to assess the safety and efficacy of larazotide acetate versus placebo in inducing remission in subjects with active celiac disease.
Study identification
- NCT ID
- NCT00620451
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 105 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2008 (Actual)
- Primary completion
- Jul 2009 (Actual)
- Completion
- Dec 2009 (Actual)
- Last update posted
- Sep 20, 2017
2008 – 2009
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Study Site | Orange | California | 92868 | — |
| Study Site | San Francisco | California | 94115 | — |
| Study Site | Torrington | Connecticut | 06790 | — |
| Study Site | Jacksonville | Florida | 32207 | — |
| Study Site | Topeka | Kansas | 66606 | — |
| Study Site | Lexington | Kentucky | 40536 | — |
| Study Site | Hagerstown | Maryland | 21740 | — |
| Study Site | Silver Spring | Maryland | 20901 | — |
| Study Site | Chesterfield | Michigan | 48047 | — |
| Study Site | Troy | Michigan | 48084 | — |
| Study Site | Rochester | Minnesota | 55905 | — |
| Study Site | Asheville | North Carolina | 28801 | — |
| Study Site | Harrisburg | North Carolina | 28075 | — |
| Study Site | Gallipolis | Ohio | 45631 | — |
| Study Site | Paoli | Pennsylvania | 19301 | — |
| Study Site | Philadelphia | Pennsylvania | 19014 | — |
| Study Site | Pittsburgh | Pennsylvania | 15243 | — |
| Study Site | Sioux Falls | South Dakota | 57105 | — |
| Study Site | Franklin | Tennessee | 37067 | — |
| Study Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00620451, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 20, 2017 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00620451 live on ClinicalTrials.gov.